Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.52 |
| ▸ | CA9 | Q16790 | 7/20 | 0.52 |
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | CA3 | P07451 | 2/20 | 0.52 |
| ▸ | CA6 | P23280 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8750946 | 0.85 | KMT2A (0.44) | TSHRHSD17B10CA2CYP2C19KMT2A | |
| SCHEMBL1018318 | 0.82 | CA2 (0.60) | TSHRHSD17B10CA12CA2CA9 | |
| SCHEMBL7869978 | 0.81 | HTT (0.62) | TSHRHSD17B10CA12CA2CA9 | |
| SCHEMBL1018690 | 0.81 | CA12 (0.57) | TSHRHSD17B10CA12CA2CA9 | |
| SCHEMBL1018750 | 0.79 | CA2 (0.62) | TSHRHSD17B10CA12CA2CA9 | |
| SCHEMBL3717203 | 0.78 | TSHR (0.53) | TSHRHSD17B10CA12CA2CA9 | |
| SCHEMBL5974400 | 0.78 | CA2 (0.53) | TSHRHSD17B10CA12CA2CA9 | |
| SCHEMBL1403608 | 0.78 | TSHR (0.61) | TSHRHSD17B10CA12CA2CA9 | |
| Hydrochloric Acid SCHEMBL11481772 | 0.78 | CYP2C19 (0.50) | TSHRCA2CA1CYP2C19KMT2A | |
| SCHEMBL798585 | 0.77 | PSIP1 (0.56) | TSHRHSD17B10CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028942-B1 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| EP-1386158-B1 | OBJECT COMPRISING AN UNCHARGED, FUNCTIONALIZED HYDROGEL SURFACE | HOFMANN ANDREAS (DE) | 2008-05-14 | — | — | EP | disclosed |
| US-20080027060-A1 | DIPEPTIDE NITRILES | ALTMANN EVA | 2008-01-31 | — | — | US | disclosed |
| US-20060235220-A1 | Dipeptide nitriles | MISSBACH MARTIN | 2006-10-19 | — | — | US | disclosed |
| US-20040157149-A1 | Object comprising an uncharged, functionalized hydrogel surface | HOFMANN, ANDREAS (DE) | 2004-08-12 | — | — | US | disclosed |
| US-20040110806-A1 | Dipeptide derivatives | ALTMANN EVA (CH) | 2004-06-10 | — | — | US | disclosed |
| US-20040029814-A1 | Dipeptide nitriles | ALTMANN EVA (CH) | 2004-02-12 | — | — | US | disclosed |
| EP-1386158-A1 | OBJECT COMPRISING AN UNCHARGED, FUNCTIONALIZED HYDROGEL SURFACE | Jandratek GmbH (DE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090988-A1 | OBJECT COMPRISING AN UNCHARGED, FUNCTIONALIZED HYDROGEL SURFACE | JANDRATEK GMBH (DE) | 2002-11-14 | — | — | WO | disclosed |
| US-6353017-B1 | INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | disclosed |
| EP-1028942-A2 | DIPEPTIDE NITRILES | Novartis AG (CH) | 2000-08-23 | — | — | EP | disclosed |
| US-5962475-A | OSTEOPOROSIS, RESTENOSIS, BREAST CANCER | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999024460-A2 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 1999-05-20 | — | — | WO | disclosed |
| EP-0838464-A1 | Substituted benzo(b)thiophene compounds having activity as selective estrogen receptor modulators | ELI LILLY AND COMPANY (US) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110806-A1 | Dipeptide derivatives | CTSL, CTSZ, CTSS | TSHR 2994/4885HSD17B10 3154/4885CA12 839/4885 |
| US-20040029814-A1 | Dipeptide nitriles | NOS1, CTSL, CTSS | TSHR 2883/4885HSD17B10 2998/4885CA12 790/4885 |
| US-20060235220-A1 | Dipeptide nitriles | CTSL, CTSS, CTSB | TSHR 2383/4885HSD17B10 3508/4885CA12 824/4885 |
| US-20080027060-A1 | DIPEPTIDE NITRILES | CTSL, CTSS, CTSB | TSHR 2383/4885HSD17B10 3508/4885CA12 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.